<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00547014</url>
  </required_header>
  <id_info>
    <org_study_id>B1221001</org_study_id>
    <secondary_id>52364-002</secondary_id>
    <nct_id>NCT00547014</nct_id>
  </id_info>
  <brief_title>First Safety Study in Humans of a Single Dose of CPG 52364</brief_title>
  <official_title>Oral Administration Of CPG 52364 In Healthy Subjects: A Phase 1, Within-Cohort Randomized, Double-Blinded, Placebo-Controlled, Ascending Single-Dose, Single-Center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the safety and tolerability of the study drug, CPG 52364, when given as liquid or
      capsule. Another purpose is to determine how the drug enters and leaves the blood stream and
      body tissues over time.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Assessment of Adverse Events</measure>
    <time_frame>28 days/subject</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters</measure>
    <time_frame>28 days/subject</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator: Cohort 1 Placebo</intervention_name>
    <description>Drug: placebo for cohort 1 as single dose</description>
    <arm_group_label>Cohort 1 1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>52364 3 mg</intervention_name>
    <description>3 mg capsule single dose administered orally as a single dose</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator: Cohorts 2, 3, 4 &amp; 5 Two subjects each arm will be assigned to receive placebo</intervention_name>
    <description>Drug: Placebo for cohorts 2, 3, 4 and 5 administered as a single dose</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>52364 10 mg</intervention_name>
    <description>Drug: 52364 30 mg capsule as a single dose</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>52364 30 mg</intervention_name>
    <description>Drug: 52364 30 mg capsule administered as a single dose</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>52364 100 mg</intervention_name>
    <description>Drug 52364 100 mg capsule administered as a single dose</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>52364 1 mg</intervention_name>
    <description>1 mg powder diluted in liquid or placebo (liquid alone) administered orally as a single dose</description>
    <arm_group_label>Cohort 1 1mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal body mass index and weight

          -  No significant diseases in the medical history or clinically significant findings on
             physical exam, opthalmologic exam, clinical laboratory evaluations or 12-lead
             electrocardiogram

        Exclusion Criteria:

          -  Current illness or history of medical condition affecting the body's function

          -  Use of any medication within 7 days, any immunosuppressive medication within 6 months,
             any investigational drug within 30 days or any vaccine or immunoglobulin within 90
             days

          -  Use of any medications during the study

          -  Positive TB test

          -  Smoking within 6 months

          -  Pregnancy or risk of Pregnancy

          -  Alcohol or drug misuse within 60 days

          -  Sensitivity to quinazolines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1221001&amp;StudyName=First%20Safety%20Study%20in%20Humans%20of%20a%20Single%20Dose%20of%20CPG%2052364</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2007</study_first_submitted>
  <study_first_submitted_qc>October 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2007</study_first_posted>
  <last_update_submitted>March 18, 2009</last_update_submitted>
  <last_update_submitted_qc>March 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>treatment, parallel assignment, double blind, randomized, placebo control, safety study,SLE (Systemic Lupus Erythematosus)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

